Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic Changes
Description
CONCLUSIONS: With ongoing COVID-19 transmission and occurrence of breakthrough infections in vaccinated individuals, including patients with cancer, therapeutic agents that target both the virus and host inflammatory response would be helpful despite
